rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Ocugen, Inc.

OCGN · Nasdaq

Health CareBiotechnologyNot moving yet

OCGN stood above a rising 150-day average in 28 of the last 52 weekly readings, and has been out of that trend for the last 24 weeks. It is 44.7% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 24
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$52K
Insider sales, 12 months
$1.7M
Officials’ trades on record
2
Institutions holding
144 (+12)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 28 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$1.1M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

2 disclosed lines: House 2, Senate 0, executive 0; 1 people.

WhoDidAmountTraded
Chris Jacobs House: U.S. House ClerkNY27sold$1k–$15k8 Nov 2022filed 12 Dec 2022
Chris Jacobs House: U.S. House ClerkNY27bought$15k–$50k16 Jun 2022filed 28 Jul 2022

Insiders

Buy orders, 12 months1
Sale orders, 12 months2
Buyers · sellers1 · 1
WhoDidSharesTraded
Shankar MusunuriChief Executive Officersold468,727at $0.959 Oct 2026filed 13 Oct 2026
Shankar MusunuriChief Executive Officersold57,264at $0.959 Oct 2026filed 13 Oct 2026
Shankar MusunuriChief Executive Officersold468,727at $1.129 Sep 2026filed 11 Sep 2026
Shankar MusunuriChief Executive Officersold57,264at $1.129 Sep 2026filed 11 Sep 2026
Treerita Essalima Johnson-GreeneChief Financial Officerbought21,000at $1.2315 Jun 2026filed 17 Jun 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders144+12 on the quarter
New · exited44 · 33
Reported value$220.3M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
BlackRock, Inc.added · filed 7 Aug 202627,002,933$41.3M+19,697,954+269.7%
STATE STREET CORPadded · filed 7 Aug 202621,469,307$32.8M+11,799,116+122.0%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 202614,372,598$22.0M+568,487+4.1%
MILLENNIUM MANAGEMENT LLCadded · filed 14 Aug 202613,943,252$21.3M+216,060+1.6%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 20268,871,013$13.6M+4,643,909+109.9%
RTW INVESTMENTS, LPunchanged · filed 14 Aug 20266,666,666$10.2M00.0%
UBS Group AGreduced · filed 13 Aug 20265,177,508$7.9M-2,102,812−28.9%
Ikarian Capital, LLCunchanged · filed 14 Aug 20263,962,972$6.1M00.0%
GMT Capital Corpunchanged · filed 14 Aug 20263,505,398$5.4M00.0%
MARSHALL WACE, LLPreduced · filed 13 Aug 20263,410,257$5.2M-4,642,093−57.6%
31 Mar 2023 – 30 Jun 2026
64103141Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

Shankar Musunuri Company insiderChief Executive Officer · last 9 Oct 20262 · 18
Treerita Essalima Johnson-Greene Company insiderChief Financial Officer · last 15 Jun 20261 · 0
Blaise Coleman Company insiderDirector · last 11 Jun 20260 · 0
Junge Zhang Company insiderDirector · last 11 Jun 20269 · 2
Kirsten Castillo Company insiderDirector · last 11 Jun 20262 · 3
Satishchandran Chandrasekhar Company insiderDirector · last 11 Jun 20260 · 0
Uday Kompella Company insiderDirector · last 11 Jun 20260 · 13
Ramesh Ramachandran Company insiderChief Accounting Officer · last 2 Jan 20260 · 0
Arun Upadhyay Company insiderOfficer · last 3 Jan 20250 · 0
Huma Qamar Company insiderChief Medical Officer · last 2 Jan 20250 · 0
Prabhavathi Fernandes Company insiderDirector · last 26 Nov 20241 · 1
Marna C. Whittington Company insiderDirector · last 28 Jun 20240 · 0

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Share count trendFY 2025 · to 24 Feb 20265.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$18.9M
Free cash flowFY 2025 · to 31 Dec 2025−$57.1M

Analyst forecasts

No analyst forecasts yet.